The disclosure relates to defective interfering genes and viruses thereof. It has been discovered that defective interfering genes designed from influenza and coronavirus species can inhibit infection or replication of the parent virus. In vivo, DIGs induce rapid-onset prophylactic protection of infected animals against lethal viral doses. Thus, disclosed herein are nucleic acids containing DIGs, pharmaceutical compositions thereof and associated methods of use. For example, described herein is an isolated polynucleotide containing one or more defective interfering genes, wherein each of the one or more defective interfering genes contains a nucleotide sequence corresponding to one or more portions of an influenza or coronavirus gene or genome, wherein the nucleotide sequence includes a deletion in the gene. The DIGs can be in the form of a plasmid. Pharmaceutical compositions of the plasmid can be used to limit viral replication and prevent or treat influenza or coronavirus associated diseases.

The present invention relates to a recombinant poxviral vector for use in vaccinating a subject against SARS-CoV-2. The present invention also provides vaccination regimens using the recombinant poxviral vector, which confers protective immunity against SARS-CoV-2.

The present invention is directed to a gram-negative bacterial host cell for vaccine use comprising a heterologous functional Actinobacillus pleuropneumoniae (APR) rfb gene cluster producing an APR O-anti-gen bound to the lipid A-core of the bacterial host cell and located on the bacterial host outer surface, and wherein the endogenous rib gene cluster of the bacterial host cell is not functional. The invention further pertains to compositions comprising said host cells, in particular vaccines, and corresponding uses in the prophylaxis and/or therapy of Actinobacillus pleuropneumoniae (APR) infections.

Dry powder compositions comprising biologically active antibodies or antibody fragments thereof are provided herein. In some aspects, the present disclosure includes methods of manufacturing these compositions and methods of using them in pulmonary administration or applying them to a tissue surface through a medical dry powder blower/sprayer/insufflator.

Antigenic molecules and compositions described herein protect against infection by typhoidal and non-typhoidal Salmonella serovars. Methods of immunization comprise the use of the antigenic molecules.

The present invention in general to intranasal mRNA vaccines, more in particular comprising one or more immunostimulatory molecules, one or more pathogenic antigens and a specifically designed delivery system. Specifically said immunostimulatory molecules and pathogenic antigens are provided for in the form of mRNA molecules encoding such molecules and antigen; more in particular mRNA molecules encoding for CD40L, caTLR4 and/or CD70 in combination with one or more mRNA molecules encoding a bacterial, viral or fungal antigen. Specifically said, the delivery is a mixture of chemical compounds that allow protection and deposition of the vaccine and targeting to the antigen presenting cells in the nose. In particular, present invention is well suited for development of a rapid response vaccine in an outbreak setting.

The present disclosure is directed to a relief system for the effective detection, prevention, and treatment of COVID-19, including (1) serological diagnostic assays for the detection of viral infection and epidemiological surveillance, (2) high-precision, site-directed peptide immunogen constructs for the prevention of infection by SARS-CoV-2, (3) receptor-based antiviral therapies for the treatment of the disease in infected patients, and (4) designer protein vaccine containing S1-RBD-sFc. The disclosed relief system utilizes amino acid sequences from SARS-CoV-2 proteins as well as human receptors for the design and manufacture of optimal SARS-CoV-2 antigenic peptides, peptide immunogen constructs, CHO-derived protein immunogen constructs, long-acting CHO-derived ACE2 proteins, and formulations thereof, as diagnostics, vaccines, and antiviral therapies for the detection, prevention, and treatment of COVID-19.

The present invention provides constructs of the parainfluenza virus type-5 (PIV5) virus expressing the SARS-CoV-2 envelope spike (S) and nucleocapsid (N) proteins of SARS-CoV-2 variants for use as safe, stable, efficacious, and cost-effective vaccines against COVID-19.

The present invention relates to an anti-infection and anti-tumor mucosal immune preparation. The mucosal immune preparation includes mucosal immune substances that are mainly formed by organically bonding polyinosinic-polycytidylic acid, non-antibiotic amino compounds and metal cations through chemical bonds. The present invention provides a slow release effect on a local part or the whole body, prevents the degradation of serum ribonucleases of human beings and primates, prolong the half-life period of the mucosal immune preparation, increases the availability and effectiveness of drugs. The mucosal immune preparation can facilitate the mucosal immunity of the body by mucosal immunity and thus facilitate the activation and proliferation of various immune cells, rather than merely acting on diseased local parts, so that the purposes of anti-infection and anti-tumor prevention and treatment with almost no side effects are realized. Mucosal immunity also avoids the pain of repeated injection so that good compliance is achieved.

Outer membrane vesicles from bacteria of the Burkholderia pseudomallei complex can be used as adjuvants in compositions and methods to potentiate the immune response to immunogens.